Genetix Announces Transformation Into a Profitable, High-Growth Commercial Leader in Rare Disease Genetic Medicine

Genetix Biotherapeutics Reports Strong 2026 Commercial Growth, Achieves Profitability and Targets Multibillion-Dollar Expansion

Genetix Biotherapeutics Inc., a commercial leader in genetic medicines for rare diseases with a primary focus on hematology, has announced a significant transformation into a profitable, high-growth commercial enterprise, supported by strong commercial performance in 2026 and a strategic plan targeting multibillion-dollar growth. The company outlined its financial achievements, expanding commercial operations, manufacturing improvements and future development priorities during a presentation delivered by Chief Executive Officer David Meek at the Jefferies Global Healthcare Conference in London, United Kingdom.

Over the past 18 months, Genetix has strengthened its commercial operations and established a hematology franchise centered on one-time gene addition cell therapies for patients with serious inherited blood disorders. Its portfolio includes LYFGENIA® (lovotibeglogene autotemcel), approved for the treatment of patients aged 12 years and older with sickle cell disease and a history of vaso-occlusive events, and ZYNTEGLO® (betibeglogene autotemcel), indicated for adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

Together, these therapies have the potential to address an estimated 105,000 patients eligible for genetic medicine across the United States and selected international markets. The company believes that its established commercial infrastructure, manufacturing capabilities and growing treatment-center network position it to expand access to these therapies and address the significant unmet medical needs of patients living with inherited blood disorders.

Genetix also highlighted its clinical experience, reporting that more than 400 patients have been treated with its gene therapies. The company has accumulated long-term durability data extending beyond 11 years, representing what it describes as the most mature clinical dataset in genetic medicine for hemoglobinopathies.

The company’s recent financial performance reflects the growing commercial adoption of its therapies. Genetix reported approximately $327 million in U.S. net sales during the first nine months of 2026, representing growth of approximately 95% compared with the corresponding period in 2025. For the full year, the company expects U.S. net sales of approximately $500 million, representing year-over-year growth of approximately 100%.

David Meek, chief executive officer of Genetix Biotherapeutics, stated that the company had transformed into a profitable, high-growth commercial enterprise within just 18 months. He emphasized that the business has demonstrated the potential for genetic medicines to deliver meaningful patient outcomes while also establishing a sustainable commercial model.

Meek highlighted the company’s expected 2026 U.S. net sales of approximately $500 million, its established hematology franchise and the significant number of eligible patients who have not yet received treatment.

He added that Genetix has established the manufacturing capacity, commercial infrastructure and operational model required to support international expansion and pursue multibillion-dollar growth opportunities. The company’s objective is to make its one-time gene therapies accessible to tens of thousands of eligible patients with sickle cell disease and beta-thalassemia who could potentially benefit from treatment.

Genetix Completes 18-Month Transformation Into a Profitable Commercial Enterprise

A major highlight of the company’s presentation was its rapid transformation into a profitable commercial organization.

Over the past 18 months, Genetix has focused on building a specialized commercial model capable of supporting the complex treatment journey associated with genetic medicines. Unlike conventional pharmaceutical products that can be prescribed and administered through relatively established distribution channels, gene therapies often require highly coordinated processes involving patient identification, referral, specialized treatment centers, manufacturing and reimbursement.

To address these requirements, the company developed a purpose-built commercial infrastructure designed around the needs of patients, healthcare professionals and treatment centers.

One of its primary priorities has been establishing a high-touch commercial model supported by disciplined execution. This approach involves targeted patient engagement, stronger relationships with healthcare providers and improved coordination throughout the treatment process.

The company has also optimized its manufacturing operations to improve reliability and increase production capacity. These improvements are intended to support a more predictable treatment experience while enabling the organization to manage increasing patient demand.

Another important development has been the expansion of treatment access across the United States. Genetix reported approximately 100 activated and qualified treatment centers, providing a broader network through which eligible patients can be evaluated and treated.

Reimbursement coverage has also improved significantly. The company reported that more than 95% of U.S. lives are covered, helping reduce financial barriers and support broader access to its therapies.

In parallel, targeted patient engagement initiatives and outreach activities have contributed to accelerating demand for LYFGENIA and ZYNTEGLO.

These commercial and operational improvements have supported the company’s transition to sustained profitability. Genetix achieved profitability in the fourth quarter of 2025 and reported that it has maintained this position since then.

The achievement represents an important milestone for the company and demonstrates the commercial potential of its specialized genetic medicine business model.

Strong 2026 Commercial Performance Supports Revenue Growth

Genetix reported substantial commercial growth during the first nine months of 2026, supported by increased patient enrollment, higher treatment activity and broader access to its gene therapies.

The company generated approximately $327 million in U.S. net sales during the first three quarters of 2026, representing an increase of approximately 95% year over year.

For the full year, Genetix expects U.S. net sales to reach approximately $500 million, approximately doubling its 2025 performance.

Patient enrollment has also continued to increase. Since 2022, more than 700 patients have enrolled for treatment with the company’s therapies. Genetix expects more than 325 additional patient enrollments during 2026 alone.

The company reported that approximately 125 patients received infusions during the first nine months of 2026, representing an increase of more than 100% compared with the same period in the previous year.

These figures indicate increasing activity across the company’s commercial treatment network.

Patient enrollment and infusion activity are particularly important performance indicators for genetic medicine companies because the treatment process involves several stages before patients receive their therapies.

The process generally requires identifying eligible individuals, conducting medical evaluations, coordinating cell collection, manufacturing the personalized therapy and arranging treatment at qualified medical centers.

By improving operational coordination and expanding treatment-center capacity, Genetix aims to reduce delays and support an increasing number of patients moving through the treatment pathway.

The company’s commercial strategy is therefore focused not only on increasing sales but also on improving the efficiency and predictability of the overall patient journey.

Manufacturing Optimization Improves Treatment Efficiency and Reliability

Manufacturing remains a central component of Genetix’s long-term growth strategy.

The company highlighted its differentiated gene-addition manufacturing technology, which it believes offers operational advantages and supports a more predictable treatment process.

Its manufacturing approach is based on electroporation-free gene addition technology, supported by decades of experience and clinical data from more than 400 treated patients.

The company also emphasized that its clinical experience includes long-term durability data extending beyond 11 years, providing an established evidence base for its genetic medicine platform in hemoglobinopathies.

During the presentation, Genetix outlined several improvements in manufacturing capacity, reliability and turnaround time.

Expanded manufacturing capacity

Genetix reported that it has doubled its manufacturing capacity, supporting a more scalable operating model for future commercial growth.

The expanded capacity is intended to create a pathway for treating thousands of patients annually as the company increases its commercial reach across the United States and international markets.

Manufacturing scalability is particularly important for personalized genetic medicines because each patient’s treatment requires a coordinated production process using their own cells.

Increasing capacity while maintaining product quality and manufacturing consistency will be essential as patient demand grows.

Improved manufacturing success rates

The company reported an approximately 90% manufacturing success rate, representing a 20% improvement since 2024.

This improvement reflects its efforts to enhance manufacturing processes, strengthen operational controls and improve production reliability.

Higher manufacturing success rates can help reduce delays and minimize the risk of repeating complex cell collection and production procedures.

Reduced number of cell collections

Genetix also highlighted improvements in the number of cell collections required for patients undergoing treatment.

At commercial scale, the median number of cell collections is now one, while more than 85% of patients have been treated within two collections.

Reducing the number of required collections can simplify the treatment process and potentially lessen the operational burden on patients and healthcare providers.

Faster manufacturing turnaround

The company has also reduced the time required to complete manufacturing activities.

Genetix reported a turnaround time of approximately 65 days from cell collection to lot disposition, which is 25 days faster than in 2024.

This improvement is intended to create a more efficient and predictable treatment journey, helping patients and healthcare teams better coordinate the steps required before infusion.

Together, these manufacturing improvements are expected to support the company’s growing commercial operations and provide a foundation for further international expansion.

LYFGENIA and ZYNTEGLO Anchor the Hematology Franchise

Genetix’s commercial strategy is centered on two gene addition cell therapies addressing serious inherited blood disorders.

LYFGENIA (lovotibeglogene autotemcel) is indicated for patients aged 12 years and older with sickle cell disease and a history of vaso-occlusive events.

Sickle cell disease is an inherited blood disorder caused by a genetic mutation affecting hemoglobin, the protein responsible for carrying oxygen throughout the body. The condition can cause red blood cells to become rigid and sickle-shaped, potentially obstructing blood flow and leading to painful vaso-occlusive events and organ complications.

LYFGENIA is a one-time gene therapy designed to modify a patient’s own hematopoietic stem cells so that they produce a form of hemoglobin intended to reduce sickling.

ZYNTEGLO (betibeglogene autotemcel) is indicated for adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

Beta-thalassemia is an inherited blood disorder involving reduced or absent production of beta-globin, a component of hemoglobin. Patients with severe disease may require repeated blood transfusions to maintain adequate hemoglobin levels.

ZYNTEGLO is designed to introduce a functional beta-globin gene into a patient’s own stem cells, enabling the production of functional hemoglobin.

Both therapies are based on personalized gene addition approaches and are intended as one-time treatments.

The company estimates that approximately 105,000 patients across the United States and selected international markets could be eligible for genetic medicine addressing these conditions.

Despite the availability of advanced treatment options, identifying eligible patients and ensuring access to specialized treatment centers remain important challenges.

Genetix plans to address these challenges through targeted patient engagement, improved referral networks and expanded commercial infrastructure.

Strategic Partnerships to Increase Patient Awareness and Treatment Access

Another important priority for Genetix is strengthening awareness of genetic medicine among patients, families and healthcare professionals.

The company plans to expand its outreach initiatives and build stronger hematology referral pathways through targeted partnerships.

One of the partnerships highlighted during the presentation involves the National Football League Alumni Association.

Through initiatives such as this, Genetix aims to increase awareness of inherited blood disorders and encourage eligible patients to explore available treatment options with qualified healthcare professionals.

Improving awareness is particularly important for rare diseases because patients may experience delays in diagnosis, referral and access to specialized treatment.

The company’s commercial approach focuses on improving connections between patients, hematologists, referral institutions and qualified treatment centers.

With approximately 100 activated treatment centers across the United States, Genetix believes it has established an important foundation for expanding patient access.

The company will continue to focus on increasing treatment-center engagement and improving the efficiency of the patient identification and enrollment process.

LYFGENIA Pediatric Expansion Advances Toward Regulatory Submission

Expanding access to LYFGENIA to younger patients with sickle cell disease is another major strategic priority.

Genetix reported that dosing has been completed in its HGB-210 clinical study, which includes patients as young as two years old.

The company plans to submit a regulatory application by the end of 2026 seeking to expand LYFGENIA’s use to U.S. patients with sickle cell disease younger than 12 years.

Currently, the therapy is indicated for patients aged 12 years and older who have a history of vaso-occlusive events.

An expansion into younger patient populations could significantly broaden the potential treatment population and provide additional opportunities to address the disease earlier in life.

Pediatric development is particularly relevant in sickle cell disease because the condition is inherited and its complications can begin during childhood.

However, younger patients require careful clinical evaluation, and regulatory review will be necessary before any expanded indication can become available.

The completion of dosing in HGB-210 represents an important development milestone as the company advances toward its planned regulatory submission.

International Expansion Creates Additional Growth Opportunities

Genetix is also advancing its global commercial strategy to expand access to LYFGENIA and ZYNTEGLO beyond the United States.

The company reported that Marketing Authorization Applications are currently under review by the Saudi Food and Drug Authority.

These applications are being pursued through its local Gulf Cooperation Council partner, SPIMACO.

The Gulf region represents an additional opportunity for the company to expand access to genetic medicines for patients with inherited blood disorders.

Genetix also plans to pursue additional international regulatory submissions in 2027.

Expanding into international markets will require regulatory approvals, local commercial partnerships, manufacturing coordination and the development of specialized treatment-center networks.

The company’s existing manufacturing infrastructure and commercial experience are expected to support these efforts.

International expansion could also help the company address the broader population of patients with sickle cell disease and beta-thalassemia who may be eligible for genetic medicine.

Additional Manufacturing Enhancements Planned

Alongside its commercial and international expansion initiatives, Genetix plans to introduce further manufacturing improvements to streamline the treatment process.

One of the planned enhancements involves cryopreserved apheresis, which could provide additional flexibility in managing patient cell collection and manufacturing logistics.

Apheresis is the process used to collect specific blood components, including the hematopoietic stem cells required for certain personalized gene therapies.

Cryopreservation involves preserving collected biological material at very low temperatures for subsequent use.

Introducing cryopreserved apheresis capabilities could help improve scheduling flexibility and coordination between cell collection, manufacturing and treatment centers.

The company intends to evaluate and implement additional operational improvements to support faster turnaround times and a more predictable treatment journey.

These initiatives are expected to complement the manufacturing capacity expansion and reliability improvements already achieved.

Genetix Positions Itself for Multibillion-Dollar Growth

Genetix Biotherapeutics’ latest presentation highlights its transition from a clinical and development-focused organization into a profitable commercial business built around genetic medicines for rare hematological diseases.

With approximately $327 million in U.S. net sales during the first nine months of 2026 and approximately $500 million expected for the full year, the company is reporting substantial commercial momentum.

Its strategy combines expanding patient access, strengthening manufacturing operations, pursuing pediatric development opportunities and entering additional international markets.

The company’s portfolio of LYFGENIA and ZYNTEGLO provides a foundation for growth across sickle cell disease and beta-thalassemia, while its clinical experience of more than 400 treated patients and durability data extending beyond 11 years support its established position in genetic medicine for hemoglobinopathies.

Looking ahead, Genetix plans to focus on sustaining profitability, increasing patient enrollments and infusions, improving manufacturing efficiency and expanding its treatment-center network.

The planned LYFGENIA pediatric regulatory submission by the end of 2026 and additional international regulatory submissions in 2027 represent important upcoming milestones.

Through these initiatives, the company aims to expand access to one-time genetic treatments for eligible patients while strengthening its position in the global rare disease market.

Genetix’s long-term objective is to translate its commercial infrastructure, manufacturing capabilities and clinical experience into multibillion-dollar growth while bringing potentially transformative genetic medicines to a larger population of patients living with serious inherited blood disorders.

About LYFGENIA™ (lovotibeglogene autotemcel)

LYFGENIAis a one-time ex-vivo lentiviral vector (LVV) gene addition therapy approved for eligible patients with sickle cell disease, in which a functional β-globin gene is added to patients’ own hematopoietic (blood) stem and progenitor cells (HSPCs). This addition results in the production of adult hemoglobin with anti-sickling properties (HbA T87Q) which has a similar oxygen-binding affinity to wild-type HbA. LYFGENIA has been shown to limit sickling of red blood cells and may decrease or stop vaso-occlusive events (VOEs).

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter